The non-invasive technology was developed for physicians to visualize abnormal blood vessels in the retina and determine an appropriate course of treatment.

Optovue founder and CEO Jay Wei said: "We are thrilled to announce FDA clearance of our AngioVue System, which will bring significant benefits of our innovative, non-invasive retinal imaging to patients in the US suffering from retinal diseases that lead to progressive blindness.

"Since we first introduced this technology to markets outside the US 14 months ago, the technology is in daily clinical use at over 525 clinical sites where it provides a more patient-friendly approach to diseases of the retina that lead to progressive blindness."

With its proprietary technology, the AngioVue system enables physicians to visualize the presence or absence of flow in the blood vessels.

According to the company, this allows the assessment of new information from the microvasculature and perfusion in ocular diseases with extraordinary detail.

The system, which is said to capture a single image in less than three seconds, does not require the use of dye injections that can often obscure the target anatomy.

Earlier this month, the firm launched new optical coherence tomography angiography (OCTA) technology, AngioAnalytics.

Available on the the AngioVue imaging system, the new OCTA technology allows clinicians to quantify the density of blood flow in the retina, the light-sensitive portion of the eye.